Stayble Therapeutics (STABL) investor relations material

Executive summary

• No significant events were communicated during Q1 2026, but active work on financing and phase 2b preparations continued.

• After the period, a control balance sheet was established as equity fell below half of registered share capital.

• A non-binding term sheet for strategic collaboration and financing was signed in May, with ongoing efforts to secure binding investment.

• The company continues preparations for a phase 2b study of STA363, targeting chronic disc herniation pain.

Financial highlights

• Operating costs for Q1 2026 were 5,859 KSEK, up from 2,066 KSEK in Q1 2025.

• EBIT for Q1 2026 was -5,854 KSEK, compared to -2,044 KSEK in Q1 2025.

• Net result for Q1 2026 was -5,862 KSEK, versus -2,044 KSEK in Q1 2025.

• Cash and cash equivalents at March 31, 2026, were 1,102 KSEK, down from 2,570 KSEK a year earlier.

• Equity at March 31, 2026, was 1,060 KSEK, below half of the registered share capital of 4,184 KSEK.

Outlook and guidance

• Liquid assets are sufficient for operations until June 2026; ongoing discussions for further financing.

• Focus remains on converting the term sheet into a binding investment agreement and securing phase 2b funding.